Equity Profile

TMDX

TransMedics Group, Inc.

Health CareHealth Care Equipment$2.6B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

TransMedics Group, Inc. operates in the health care sector, focusing on innovative equipment for organ transplantation....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and drive future profitability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TMDX Q2-2026 Earnings Preview

Context

Company Snapshot

TransMedics Group, Inc. operates in the health care sector, focusing on innovative equipment for organ transplantation. Their technology aims to improve the success rates of organ transplants, which is crucial as demand for organ donations continues to rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+101.46%

Avg Stock Reaction

+0.63%

Last Quarter Recap

In Q1-2026, TransMedics reported an EPS of $0.30, which was significantly below the estimated $0.62, resulting in a stock decline of 2.21% the following day. This miss raised concerns about the company's growth trajectory.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the upcoming earnings report, especially after the significant EPS miss last quarter. There is uncertainty about whether the company can rebound and meet or exceed expectations this time.

Bull Case

If TransMedics can demonstrate strong revenue growth and improved operational efficiency, it may restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to show progress in its financial performance or provides weak guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to analyst expectations?

Given the significant miss last quarter, the market will closely scrutinize EPS to gauge the company's recovery and growth potential.

What specific revenue growth figures can management provide?

Investors are looking for clear indicators of growth to validate the company's strategy and operational effectiveness.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in EPS and revenue growth based on historical performance and recent operational improvements.

Supporting Evidence

TransMedics has a strong track record of beating EPS estimates 75% of the time.

The significant implied move in options suggests that traders expect a more substantial reaction than what has been historically realized.

Key Risk

If the EPS comes in above $0.62, it could challenge the current bearish sentiment and shift the narrative around the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical for assessing whether TransMedics can regain investor confidence after a disappointing previous quarter.

Bull Confirmed If

An EPS of $0.62 or higher would confirm a strong recovery and positive momentum.

Bear Confirmed If

An EPS below $0.30 would indicate ongoing struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±37.24%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±37.2% while TMDX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

92.1%

Calls (97K)P/C Ratio: 2.57Puts (106K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TransMedics beats expectations, history suggests the stock could rise by around 1.07%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses again, history suggests a potential decline of about 0.68%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technology advancements in organ transplantation.
2Management's commentary on operational efficiencies and cost management strategies.
3Insights into market demand for organ transplants and how the company is positioning itself.
4Guidance on revenue expectations for the next quarter and beyond.
5Responses to analyst questions regarding the previous quarter's performance and future outlook.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

TransMedics Group, Inc. operates in the health care sector, focusing on innovative equipment for organ transplantation....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and drive future profitability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TMDX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+101.46%

Avg Stock Reaction

+0.63%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If TransMedics can demonstrate strong revenue growth and improved operational efficiency, it may restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to show progress in its financial performance or provides weak guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to analyst expectations?

Given the significant miss last quarter, the market will closely scrutinize EPS to gauge the company's recovery and growth potential.

What specific revenue growth figures can management provide?

Investors are looking for clear indicators of growth to validate the company's strategy and operational effectiveness.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in EPS and revenue growth based on historical performance and recent operational improvements.

Supporting Evidence

TransMedics has a strong track record of beating EPS estimates 75% of the time.

The significant implied move in options suggests that traders expect a more substantial reaction than what has been historically realized.

Key Risk

If the EPS comes in above $0.62, it could challenge the current bearish sentiment and shift the narrative around the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical for assessing whether TransMedics can regain investor confidence after a disappointing previous quarter.

Bull Confirmed If

An EPS of $0.62 or higher would confirm a strong recovery and positive momentum.

Bear Confirmed If

An EPS below $0.30 would indicate ongoing struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±37.24%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±37.2% while TMDX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

92.1%

Calls (97K)P/C Ratio: 2.57Puts (106K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TransMedics beats expectations, history suggests the stock could rise by around 1.07%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses again, history suggests a potential decline of about 0.68%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technology advancements in organ transplantation.
2Management's commentary on operational efficiencies and cost management strategies.
3Insights into market demand for organ transplants and how the company is positioning itself.
4Guidance on revenue expectations for the next quarter and beyond.
5Responses to analyst questions regarding the previous quarter's performance and future outlook.